AstraZeneca PLC American Depositary Shares (AZN)
NASDAQ (NGS) NASDAQ (NGS) Primary 
Astrazeneca (AZN) Reports Q1 Earnings: What Key Metrics Have to Say
The headline numbers for Astrazeneca (AZN) give insight into how the company performed in the quarter ended March 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
AZN Q1 Earnings Beat, Stock Down on Soft Sales Performance of Key Drugs
AstraZeneca reports mixed first-quarter 2025 results. The fall in pre-market is likely due to the soft sales performance of key drugs across the oncology and rare disease segments.
AstraZeneca shows its strength despite sales miss
AstraZeneca PLC (LSE:AZN) has once again shown why it sits at the top table of global pharmaceuticals. Although first-quarter sales missed City forecasts by a whisker, profits came in well ahead of expectations, keeping the company firmly on track for a year of solid growth.
AstraZeneca Sales, Earnings Rise; Warns of Mounting Legal Challenges in China
The drugmaker posted increased core earnings per share and sales for the first quarter, but also said it could face a fine of up to $8 million in China.
AstraZeneca shares fall 4% after Q1 revenue miss
Shares in AstraZeneca PLC (LSE:AZN) fell 4% in early trading after first-quarter revenues missed City forecasts, as investors looked past stronger-than-expected earnings and a standout performance from its oncology portfolio. The Anglo-Swedish drugmaker reiterated its guidance for the full year, forecasting high single-digit percentage growth in total revenue and a low double-digit percentage rise in core earnings per share at constant exchange rates.
AstraZeneca says may face further import tax fine from China
AstraZeneca on Tuesday said it had received an opinion from authorities in Shenzhen city of suspected unpaid import taxes of $1.6 million, adding that a fine of one to five times that amount may be levied if the company is found liable.
Tempus AI Stock Sees 21% Gain in 3 Days: Is it a Buy After AZN Deal?
Tempus AI TEM has skyrocketed 21% in the last three days, fueled by news of a $200 million partnership with AstraZeneca AZN and Pathos AI. The multi-year deal focuses on building a multimodal AI-driven foundation model for oncology, using TempusAI's de-identified oncology data.
Unveiling Astrazeneca (AZN) Q1 Outlook: Wall Street Estimates for Key Metrics
Get a deeper insight into the potential performance of Astrazeneca (AZN) for the quarter ended March 2025 by going beyond Wall Street's top -and-bottom-line estimates and examining the estimates for some of its key metrics.
Tempus AI shares jump on new oncology AI partnerships with AstraZeneca, Pathos
Tempus AI (NASDAQ:TEM) said on Wednesday it has signed multi-year strategic collaborations with AstraZeneca (AZN.L) and Pathos AI to co-develop what it called the largest multimodal foundation model in oncology, sending its shares up more than 15% in morning trading. The deals, which include $200 million in data licensing and model development fees to Tempus, will leverage the company's vast repository of de-identified oncology data and artificial intelligence capabilities to help identify new drug targets and advance cancer therapies.
AstraZeneca CEO says Europe must protect its health sovereignty, is falling behind on pharma investments
AstraZeneca Chief Executive Officer Pascal Soriot said on Wednesday that Europe has stepped up its defence spending and now must protect its health sovereignty amid a shifting world order.
Astrazeneca (AZN) Rises But Trails Market: What Investors Should Know
The latest trading day saw Astrazeneca (AZN) settling at $67.87, representing a +1.45% change from its previous close.
AstraZeneca reports best trial results in a decade for metastatic breast cancer treatment
AstraZeneca PLC (LSE:AZN) reported notable progress in ongoing trials of patients with metastatic breast cancer using a combination of drugs, Enhertu and pertuzumab. Enhertu, jointly developed by the Anglo-Swedish drug company and Japan's Daiichi Sankyo, is being combined with Roche's pertuzumab in the DESTINY-Breast09 Phase III trials, and showed a statistically significant and clinically meaningful improvement in progression-free survival.
